Back to compounds

COMPOUND PROFILE / PROTEINS & BIOLOGICS

IGF-1 LR3.

Research draft

IGF-1 LR3 is a modified IGF-1 analogue used in research and enhancement markets.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

IGF-1 LR3 is a modified IGF-1 analogue used in research and enhancement markets.

CLASSIFICATIONProteins & biologics
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

Its altered sequence affects interactions with IGF-binding proteins; it is not native IGF-1.

Human research

A reliable direct clinical evidence base for current LR3 products was not established.

Preclinical & other research

Laboratory IGF signalling does not establish human efficacy or safety for this analogue.

Safety & unknowns

Altered exposure, hypoglycaemia potential and growth-related effects remain insufficiently assessed clinically.

Regulatory status

No therapeutic approval is established here; mecasermin's approval is not applicable.

Reported use & evidence

Research profile draft

The supplied IGF-1 LR3 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Follow the cited records and registered research. Profiles remain research drafts.

Explore more compounds